Evidence map›Paper›PMID 35621697›Full record

ArticleDiabetes care2022

Association of HLA-DQ Heterodimer Residues -18β and β57 With Progression From Islet Autoimmunity to Diabetes in the Diabetes Prevention Trial-Type 1.

Lue Ping Zhao, Jay Skyler, George K Papadopoulos, Alberto Pugliese, James Antonio Najera, George P Bondinas, Antonis K Moustakas, Ruihan Wang, Chul-Woo Pyo, Wyatt C Nelson and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Lue Ping ZhaoPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Jay SkylerDiabetes Research Institute and Division of Endocrinology, Diabetes and Metabolism, University of Miami Miller School of Medicine, Miami, FL.
George K PapadopoulosLaboratory of Biophysics, Biochemistry, Biomaterials and Bioprocessing, Faculty of Agricultural Technology, Technological Educational Institute of Epirus, Arta, Greece.
Alberto PuglieseDiabetes Research Institute and Division of Endocrinology, Diabetes and Metabolism, University of Miami Miller School of Medicine, Miami, FL.
James Antonio NajeraSchool of Public Health, University of Washington, Seattle, WA.
George P BondinasDepartment of Food Science and Technology, Faculty of Environmental Sciences, Ionian University, Argostoli, Kefalonia, Greece.
Antonis K MoustakasDepartment of Food Science and Technology, Faculty of Environmental Sciences, Ionian University, Argostoli, Kefalonia, Greece.
Ruihan WangClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Chul-Woo PyoClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Wyatt C NelsonClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Daniel E GeraghtyClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Åke LernmarkDepartment of Clinical Sciences, Lund University Clinical Research Centre, Skåne University Hospital, Malmö, Sweden.ORCID 0000-0003-1735-0499
Fred Hutch Cancer Center · USIonian University · GRUniversity of Miami · USUniversity of Washington · USLund University · SETechnological Educational Institute of Epirus · GR

Funding

Discovering Conformational Regulatory Segments (CRS) Responsible for Progression from Seroconversion to Type 1 DiabetesR56DK117276 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GERAGHTY, DANIEL E., LERNMARK, AKE · 2018 to 2018
$436k
NIDDK NIH HHS R56 DK117276
6 · The paper itself

Abstract

objectiveThe purpose was to test the hypothesis that the HLA-DQαβ heterodimer structure is related to the progression of islet autoimmunity from asymptomatic to symptomatic type 1 diabetes (T1D). RESEARCH DESIGN AND

methodsNext-generation targeted sequencing was used to genotype HLA-DQA1-B1 class II genes in 670 subjects in the Diabetes Prevention Trial-Type 1 (DPT-1). Coding sequences were translated into DQ α- and β-chain amino acid residues and used in hierarchically organized haplotype (HOH) association analysis to identify motifs associated with diabetes onset.

resultsThe opposite diabetes risks were confirmed for HLA DQA1*03:01-B1*03:02 (hazard ratio [HR] 1.36; P = 2.01 ∗ 10-3) and DQA1*03:03-B1*03:01 (HR 0.62; P = 0.037). The HOH analysis uncovered residue -18β in the signal peptide and β57 in the β-chain to form six motifs. DQ*VA was associated with faster (HR 1.49; P = 6.36 ∗ 10-4) and DQ*AD with slower (HR 0.64; P = 0.020) progression to diabetes onset. VA/VA, representing DQA1*03:01-B1*03:02 (DQ8/8), had a greater HR of 1.98 (P = 2.80 ∗ 10-3). The DQ*VA motif was associated with both islet cell antibodies (P = 0.023) and insulin autoantibodies (IAAs) (P = 3.34 ∗ 10-3), while the DQ*AD motif was associated with a decreased IAA frequency (P = 0.015). Subjects with DQ*VA and DQ*AD experienced, respectively, increasing and decreasing trends of HbA1c levels throughout the follow-up.

conclusionsHLA-DQ structural motifs appear to modulate progression from islet autoimmunity to diabetes among at-risk relatives with islet autoantibodies. Residue -18β within the signal peptide may be related to levels of protein synthesis and β57 to stability of the peptide-DQab trimolecular complex.

Indexed as

Diabetes Mellitus, Type 1Islets of LangerhansAutoantibodiesAutoimmunityGenetic Predisposition to DiseaseHaplotypesHLA-DQ alpha-ChainsHLA-DQ AntigensHLA-DQ beta-ChainsHumansProtein Sorting SignalsAutoantibodiesHLA-DQ alpha-ChainsHLA-DQ AntigensHLA-DQ beta-ChainsProtein Sorting Signals

Identifiers

PMID35621697
PMCPMC9274226
OpenAlexW4281669084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.